Werewolf Therapeutics Q1 net loss narrows as expenses fall

Werewolf Therapeutics, Inc.

Werewolf Therapeutics, Inc.

HOWL

0.00


Overview

  • U.S. biopharmaceutical firm's Q1 net loss narrowed yr/yr as operating expenses declined

  • Company entered asset purchase agreement with Jazz Pharmaceuticals for IFNα program

  • All obligations under loan agreement with K2 HealthVentures repaid after quarter end


Outlook

  • Company plans to update cash runway guidance in the near future


Result Drivers

  • LOWER R&D SPENDING - Q1 research and development expenses declined yr/yr, contributing to narrower net loss


Company press release: ID:nGNX4PxJl1


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q1 Net Income

-$13.53 mln

Q1 Basic EPS

-$0.28

Q1 Operating Expenses

$13.27 mln

Q1 Operating Income

-$13.27 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Werewolf Therapeutics Inc is $7.00, about 976.6% above its May 6 closing price of $0.65


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.